Chongqing Precision Biotech Co., Ltd

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1/2
BCMACell therapy
Multiple Myeloma
Phase 1/2
CD123Cell therapy
Acute Myeloid Leukemia
C-4-29No recent activity
Phase 1
BCMA; CD70Cell therapy
Multiple Myeloma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)Phase 1/2Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
Est. primary completion 2026-12-31 · NCT04776330 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.